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Summary
R-etodolac, a nonsteroidal anti-inflammatory drug, inhibits the progression of CWRSA6 androgen-independent and LuCaP-
35 androgen-dependent prostate cancer xenograft growth through downregulation of cyclin D1 expression via the PPAR
pathway. PPAR protein degradation, observed post-R-etodolac treatment, resulted from phospho-MAP kinase (p44/42)
induction by R-etodolac negatively regulating PPAR function. Negative regulation of PPAR was overcome by a combina-
tion regimen of R-etodolac with the HER-kinase axis inhibitor, rhuMab 2C4, which demonstrated an additive antitumor
effect. We further show that the inhibition of HER-kinase activity by rhuMab 2C4 is sufficient to inhibit PPAR protein
degradation. This study introduces a novel concept of an in vivo crosstalk between the HER-kinase axis and PPAR
pathways, ultimately leading to negative regulation of PPAR activity and tumor growth inhibition.
Introduction activation in various forms of cancer. Activation of PPAR by
pioglitazone, a PPAR ligand, blocks the cell cycle and causes
differentiation of primary liposarcoma cells in culture (TontonozPeroxisome proliferator-activated receptors (PPARs) are mem-
bers of the nuclear hormone receptor superfamily and act as et al., 1997). Subsequently, it was demonstrated that treatment
of liposarcoma patients with thiazolinediones (TZDs) resultedligand-induced transcription factors. Upon ligand stimulation,
these receptors form heterodimers with a retinoid X receptor in retardation of growth and induction of differentiation of the
tumor cells (Tontonoz et al., 1997). Troglitazone, a current therapy(RXR) and bind to peroxisome proliferator response elements
(PPREs), modulating the rate of transcription of target genes for the treatment of diabetes, is well established as an antitumori-
genic compound, inhibiting the growth of colon, breast, and pros-(Sporn et al., 2001). Three isoforms of PPAR have been identi-
fied, , , and , which are encoded by separate genes. PPAR tate cancer xenografts (Elstner et al., 1998; Kubota et al., 1998;
Sarraf et al., 1998). Such observations have encouraged contin-has been further characterized into three subtypes, PPAR1,
PPAR2, and PPAR3, that are derived from distinct transcription ued research into the development of novel PPAR ligands for
the treatment of carcinogenesis.start sites followed by alternate splicing events (Fajas et al.,
1998; Green, 1995; Zhu et al., 1995). No significant functional Recently, attention has been focused on the antiproliferative
activity of nonsteroidal anti-inflammatory drugs (NSAIDs) in can-difference between the PPAR variants has been reported; how-
ever, the relative expression of these variants is tissue specific. cerous or transformed cells, which is mediated through an inter-
action with PPAR (Na and Surh, 2003). Etodolac is one suchPPAR1 appears to be expressed in several tissues, while ex-
pression of PPAR2 is primarily restricted to adipocytes (Fajas novel NSAID (Demerson et al., 1983). Etodolac is pyranocarboxylic
acid, chemically designated as () 1,8-diethyl-1,3,4,9-tetrahy-et al., 1997).
Studies suggesting that PPAR ligands inhibit cell prolifera- dropyrano-[3,4-b]indole-1-acetic acid. It exhibits anti-inflamma-
tory, analgesic, and antipyretic activities. The molecular basis fortion while inducing adipocyte differentiation (Tontonoz et al.,
1994b) have led to the investigation of the effects of PPAR the therapeutic actions of NSAIDs are believed to be through
S I G N I F I C A N C E
This manuscript demonstrates the clinical utility of R-etodolac, a novel PPAR transactivator, in prostate cancer xenografts. In addition,
the ability of R-etodolac to regulate the levels of PPAR in a cell through the induction of phospho-MAP kinase via the HER-kinase
axis is demonstrated. This is a report of crosstalk between these axes. The clinical utility of this crosstalk is demonstrated by additive
growth inhibitory properties of R-etodolac and 2C4, a HER-2-specific monoclonal antibody currently in Phase II clinical trials. Our
successful use of this combination treatment regimen demonstrates the potential utility of 2C4 to increase sensitivity of epithelial
cancers to PPAR ligands.
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Figure 1. R-etodolac transactivates PPAR
A: Etodolac is a member of the nonsteroidal anti-inflammatory drug (NSAIDs) family. It is a pyranocarboxylic acid, chemically designated as () 1,8-diethyl-
1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid. Due to its chiral center (indicated by an arrow), etodolac exists as an enantiomeric mixture of
R-etodolac and S-etodolac.
B: Transactivation of a PPAR reporter construct (AOx)3-TK-Luc by increasing concentrations of etodolac, indomethacin, and rosiglitazone in RAW 267.4
mouse macrophages. Results are presented as a fold-induction of luciferase expression relative to the no drug treatment control and are expressed as
the mean  SD of three separate experiments. Transfection efficiency was normalized using a CMV--gal reporter construct.
C: Enhancement of phorbol ester (TPA) induced expression of the CD36 scavenger receptor in THP-1 cells by etodolac and troglitazone (TGZ). Increase
in CD36 expression was determined by flow cytometry in presence or absence of TPA with the indicated drugs. Data are presented as the difference in
mean fluorescence between anti-CD36 antibody and control isotype-matched antibody.
D: Lipid accumulation in NIH3T3-PPAR cells induced by R-etodolac. NIH3T3 cells expressing recombinant PPAR were treated for 7 days with (1) vehicle
(DMSO) alone, (2) 1 M Troglitazone, (3) 1 M R-etodolac, or (4) 500 M R-etodolac. The cells were stained for neutral lipids with oil red O stain. The
photographs are displayed as a 400 magnification. The dark spots specify the accumulation of neutral lipids.
inhibition of cyclooxygenase (COX) activity, thereby blocking (Segawa et al., 2002). Hemizygous deletion of PPAR is com-
mon in primary human prostate cancers, suggesting that lossthe production of prostaglandins (PGs). However, there is a
need to determine the chemopreventative and antimetastatic of function may contribute to the malignant phenotype (Mueller
et al., 2000). In accordance with this observation, PPAR activa-effects of NSAIDs that can be separated from COX inhibition,
because COX inhibition leads to many undesirable side effects tion with synthetic ligands downregulates prostate-specific anti-
gen (PSA) mRNA expression in prostate cancer cells in vitro(Allison et al., 1992). Due to its chiral center, etodolac exists as
an enantiomeric mixture of R- and S-etodolac (Figure 1A). Unlike (Hisatake et al., 2000; Kubota et al., 1998). Moreover, a phase
II clinical study with troglitazone in patients with prostate cancerall other chiral NSAIDs, the two enantiomers of etodolac are not
metabolically interconvertible. The etodolac analog, R-etodolac was associated with prolonged periods of stable disease char-
acterized by the absence of new metastases or disease-related(SDX-101), lacks COX inhibitory activity and is considered the
“inactive” enantiomer of this drug (Adachi et al., 2004; Demerson symptoms (Mueller et al., 2000).
The HER-kinase signaling network is active in prostate can-et al., 1983). It was recently demonstrated to inhibit transcription
of a -catenin-dependent T cell and lymphoid enhancing tran- cer cells and is known to contribute significantly to the progres-
sion of the disease (Agus et al., 2002). The human epidermalscription factor (TCF/LEF) reporter gene in HEK293 cells, and
at the same concentrations, to diminish the in vitro survival growth factor receptor (HER) or ErbB family of receptor tyrosine
kinases (RTKs) are important mediators of cell growth, survival,of chronic lymphocytic leukemia (CLL) cells (Lu et al., 2004).
R-etodolac is currently being tested in Phase II clinical trials for and differentiation. The family consists of four distinct receptors,
HER1, HER2, HER3, and HER4 and at least 11 known ligandstreating CLL.
PPAR is significantly expressed in primary prostate cancer that have specificity to these receptors (Yarden and Sliwkowski,
2001). The signaling network is activated by receptor-specificbut at very low levels in normal prostate tissue, making it a
promising candidate for molecular therapy in prostate cancer ligand stimulation that leads to receptor dimerization and auto-
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Figure 2. Effect of R-etodolac on PPAR1-positive
prostate cancer xenografts
A: Representative Western blot analysis showing
PPAR1 expression in protein lysates prepared
from androgen-independent CWRSA6 and an-
drogen-dependent LuCaP-35 human prostate
cancer xenografts.
B: The response of CWRSA6 or LuCaP-35 tumors
to R-etodolac (closed diamond) administered at
a dosage of 200 mg/kg via daily o.g. or vehicle-
treated control (open diamond). Therapy was
initiated on day 6 in the CWRSA6 tumor line and
on day 9 in the LuCaP-35 tumor line. Results are
presented as mean tumor volume (n  10)  SE.
phosphorylation. Therapies directed against the HER-kinase R-etodolac enhances reporter gene expression in a dose-
dependent manner driven by promoters containing PPRE se-axis, such as rhuMab 2C4 (Agus et al., 2002), inhibit the growth
of prostate xenografts by as much as 80%, corroborating the quences in transient transfection assays (Figure 1B). This trans-
activation function is mediated only in the presence of recombi-concept that the HER-kinase axis is an important mediator of
prostate cancer growth. In vivo studies have demonstrated that nant PPAR. The COX inhibitory analog of etodolac, S-etodolac,
can also transactivate PPAR but to significantly lower levels.ligands for the HER-kinase axis induce phosphorylation of
PPAR1 by mitogen-activated protein (MAP) kinase (Camp and Transactivation by 100 M R-etodolac (13-fold) is comparable
to 10 M of the known PPAR ligand and NSAID, indomethacin,Tafuri, 1997), which may eventually regulate the levels of PPAR.
However, none of the studies have suggested a direct modula- suggesting that R-etodolac has PPAR transactivation activity.
Rosiglitazone, another demonstrated PPAR ligand, was usedtion of the HER-kinase axis by a PPAR activator. The hypothe-
sis for the crosstalk between the HER-kinase axis and the as a positive control. (2) The combination of PPAR- transactiva-
tion, together with protein kinase C activation by a phorbol ester,PPAR pathway seems plausible since the former is overex-
pressed to appreciable levels in prostate cancer. has been reported to induce the scavenger receptor CD36 in
macrophages (Han and Sidell, 2002). CD36 is documented asIn this study, we report the mechanism of action of R-etodo-
lac in inhibiting tumor growth of two prostate cancer xenograft a PPAR-regulated gene (Tontonoz et al., 1998). Using CD36
expression as a downstream indicator, 200 M of racemic eto-models, i.e., the androgen-independent CWRSA6 and the an-
drogen-dependent LuCaP-35. R-etodolac exhibits PPAR-spe- dolac and 20 M of troglitazone (a demonstrated PPAR- acti-
vator) displayed equivalent potency as measured by a flow cyto-cific activity and has the putative ability to modulate the HER-
kinase axis. Treatment with R-etodolac leads to the induction metric assay (Figure 1C). (3) PPAR is accepted as a master
regulator of adipocyte differentiation. Uptake of neutral lipids isof phospho-MAP kinase activity via the HER-kinase axis, re-
sulting in the degradation of the PPAR protein. Combination a marker of adipocyte differentiation, and oil red O staining of
these neutral lipids is an accepted procedure to demonstratetherapy with HER-kinase inhibitor rhuMab 2C4 (Agus et al.,
2002) inhibited R-etodolac-induced activation of MAP kinase, this differentiation phenomenon (Tontonoz et al., 1998). NIH3T3
cells that stably overexpress retrovirally expressed recombinantultimately preventing the degradation of PPAR protein, thereby
increasing the antitumor efficacy of the PPAR transactivator PPAR were obtained from Dr. Ronald Evans (Salk Institute,
La Jolla, CA). Cells treated with 1 M R-etodolac displayedin prostate cancer xenografts. This study highlights a novel
crosstalk mechanism between the PPAR pathway and the accumulation of neutral lipids and morphological changes asso-
ciated with PPAR activity that are comparable to those ob-HER-kinase axis that cooperates in prostate tumor growth and
further demonstrates that this crosstalk can be successfully served with troglitazone at a similar concentration (Figure 1D).
The lipid uptake was dose dependent and was significantlyinhibited with a drug combination therapy targeting these signal-
ing pathways. more pronounced at 500 M concentration of R-etodolac.
NIH3T3 cells transfected with the empty retroviral vector did
not demonstrate the lipid uptake with either troglitazone orResults
R-etodolac (data not shown). Having demonstrated that PPAR
could be transactivated by R-etodolac, the possibility of usingR-etodolac transactivates PPAR
We used three different assays to demonstrate that R-etodolac it as a potential therapeutic against prostate tumor models was
considered.has the ability to function as a PPAR transactivator. (1)
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Figure 3. Reduction in cyclin D1 mRNA and protein expression in LNCaP cells
treated with R-etodolac
A: Real-time quantitative RT-PCR assay demonstrating cyclin D1 mRNA ex-
pression in LNCaP cells treated with increasing concentrations of R-etodolac
(0, 200, and 400 M) for 18 hr. The levels of RNA were normalized using an
assay for 18S RNA. The level of cyclin D1 transcripts in untreated cells was
Figure 4. Degradation of PPAR protein following R-etodolac treatment inset to 100 percent. This graph represents the mean from three independent
CWRSA6 and LuCaP-35 prostate cancer xenograftsexperiments  SD.
B: Western blot analysis demonstrating cyclin D1 protein expression in LNCaP A: Western blot analysis demonstrating PPAR1 expression in protein lysates
cells treated with increasing concentrations of R-etodolac (0, 200, 400, and prepared from the R-etodolac efficacy studies involving the CWRSA6 and
600 M) for 18 hr. -actin protein is used as a normalization control. This LuCaP-35 human prostate cancer xenografts. Lanes 3, 4, 7, and 8 represent
figure is representative of at least 3 independent assays. vehicle-treated control tumors, whereas lanes 1 and 2 represent CWRSA6
tumors following 19 days of treatment with R-etodolac, and lanes 5 and 6
represent LuCaP-35 tumors following 13 days of treatment with R-etodolac.
Equal protein loading was confirmed with a -actin antibody.
R-etodolac, a PPAR transactivator, inhibits B: Real-time quantitative RT-PCR analysis of PPAR1 mRNA rexpression in
CWRSA6 and LuCaP-35 xenografts following the animal efficacy studies.the growth of CWRSA6 and LuCaP-35
Levels of PPAR mRNA expression were normalized to -actin mRNA levels,prostate cancer xenografts
and results are displayed as an average (n  5) relative percentage toImmunoblot analyses demonstrated the presence of PPAR1 in control animals  SD. No significant difference was observed between
the androgen-dependent LuCaP-35 and androgen-independent treated and nontreated control animals.
CWRSA6 xenografts (Figure 2A). Real-time RT-PCR further con-
firmed the presence of PPARmRNA in the xenografts (data not
shown). Primers specific for PPAR2 did not yield an appreciable
amplification, whereas total PPAR-specific primers led to a protein (Figure 3B) expression following 18 hr of R-etodolac
robust amplification, suggesting that the predominant isoform treatment of LNCaP prostate cancer cells. The decrease in
in the prostate cancer xenografts was PPAR1. To examine the cyclin D1 expression was dependent upon increasing concen-
effect of R-etodolac treatment on tumor cell growth, animals trations of R-etodolac. The inhibition of cyclin D1 expression
with established androgen-independent CWRSA6 or androgen- by R-etodolac provides insight into the mechanism by which
dependent LuCaP-35 prostate cancer xenografts were adminis- R-etodolac inhibits tumor growth.
tered R-etodolac (200 mg/kg o.g. daily). At this dose, no lethal
toxicity or weight loss (greater than 10% body weight) was R-etodolac treatment leads to a degradation
observed among treated animals, and a drug concentration of of PPAR protein
500M was achieved in the serum (data not shown). R-etodolac PPAR protein levels were analyzed in prostate xenografts fol-
demonstrated significant tumor growth inhibition in the andro- lowing R-etodolac treatment to elucidate the growth-inhibitory
gen-independent CWRSA6 xenografts (66% growth inhibition,
mechanism of R-etodolac on prostate xenografts. Since tran-
p  0.002, n  10) and androgen-dependent LuCaP-35 xeno-
sient transfection studies indicated that R-etodolac serves asgrafts (46% growth inhibition, p  0.0103, n  10) relative to
a PPAR transactivator, we expected an upregulation or nocontrol-treated animals (Figure 2B). These studies demonstrate
change in PPARprotein since the drug had caused a significantthat R-etodolac inhibits the growth of PPAR-positive prostate
reduction in tumor growth. To our surprise, the PPAR proteincancer xenografts.
was completely eliminated from the tumors following 2–3 weeks
of drug treatment as compared to the vehicle-treated controlR-etodolac causes a downregulation
(Figure 4A). Real-time RT-PCR analysis of PPAR1 mRNA at thisin cyclin D1 expression
time point showed that expression was similar to that in the controlPPAR transactivation is well documented to have an effect on
animals (Figure 4B), indicating that PPAR downregulation wascell cycle progression through the repression of the cyclin D1
predominantly a posttranscriptional event.promoter (Qin et al., 2003; Wang et al., 2003). Accordingly, we
observed a downregulation in cyclin D1 mRNA (Figure 3A) and We analyzed phospho-ERK1 and phospho-ERK2 levels fol-
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Figure 5. R-etodolac treatment increases phos-
pho-ERK activity in CWRSA6 xenografts and
22Rv1 prostate cancer cells
A: Western blot analysis of lysates prepared from
R-etodolac-treated CWRSA6 xenografts follow-
ing the time course experiment as described in
the Experimental Procedures. Animals received
R-etodolac every 24 hr; lanes 1 and 2 represent
tumors following 24 hr of treatment, lanes 4 and
5 represent tumors following 48 hr of treatment,
and lanes 5 and 6 represent tumors following 72
hr of treatment with R-etodolac. Lanes 7 and 8
represents vehicle-treated control animals fol-
lowing 72 hr of treatment. Equal loading was
confirmed with a -actin antibody, as well as
with an antibody against total MAP kinase.
B: Whole-cell lysates were prepared from 22Rv1
cells treated with R-etodolac (500M) for various
times shown. This was a representative experi-
ment repeated independently three times.
lowing R-etodolac treatment since it has been reported that treated CWRSA6 xenografts with a regimen of R-etodolac in
combination with rhuMab 2C4. rhuMab 2C4 (Agus et al., 2002)PPAR phosphorylation by MAP kinase leads to negative regu-
lation of the nuclear receptor’s function via the ubiquitin proteo- is a humanized monoclonal antibody that abrogates MAP kinase
activation by sterically inhibiting ligand-induced heterodimeriza-some-mediated degradation pathway (Floyd and Stephens,
2002). Using a phospho-specific MAP kinase antibody, we ob- tion of HER2 with members of the HER-kinase receptor family.
Mice bearing established CWRSA6 xenografts received mo-served a sharp increase in phosphorylated p44/42 levels 24 hr
post-R-etodolac treatment (Figure 5A). This transient increase notherapy with either R-etodolac (200 mg/kg o.g. daily, n  10)
or 2C4 (20 mg/kg i.p. 2/wk, n  10) or a combination regimenwas followed by a low level of sustained activation of MAP
kinase throughout the rest of the time course up to 72 hr. At 3 of R-etodolac and 2C4 for 3 weeks (n  10). At these doses,
no lethal toxicity or significant weight loss was observed amongweeks post drug treatment, immunoblot analysis of phospho-
ERK1/2 protein appeared similar to that at 72 hr (data not treated animals. CWRSA6 xenografts receiving a combination
regimen of R-etodolac and 2C4 demonstrated significant tumorshown). No difference was observed in total MAP kinase expres-
sion, and equal loading was confirmed with an anti--actin anti- inhibition compared to animals receiving R-etodolac monother-
apy (tumor inhibition 59%, p 	 0.001, n  10) and 2C4 alonebody. These results in the prostate cancer xenograft were later
confirmed in vitro by treating 22Rv1 prostate cancer cells with (tumor inhibition 51%, p  0.001, n  10) (Figure 6A). These
results support the hypothesis that the efficacy of R-etodolaca concentration of R-etodolac (500 M) physiologically similar
to that achieved in the xenograft studies. A transient peak in can be improved by inhibiting phospho-MAP kinase.
One prediction in accordance with our hypothesis would bephospho-MAP kinase activation, although modest as compared
to the in vivo studies, was observed within 20 min of the addition the rescue of PPAR protein from degradation following the
combination treatment. To ascertain this, total cell lysates wereof R-etodolac and then maintained a sustained level of activation
(Figure 5B). Such transient upregulation in phospho-MAP kinase prepared from xenografts in the preceding study and were sub-
jected to immunoblot analysis for PPAR protein. As expected,activation, also observed with troglitazone treatment, ultimately
led to degradation of PPAR protein (Baek et al., 2003). samples treated with R-etodolac alone had a complete ablation
These results suggest that R-etodolac (200 mg/kg o.g. daily) of the PPAR protein (Figure 6B, lanes 1 and 2), and animals
treatment exerts two opposing effects on tumor growth. Not receiving a combination regimen of R-etodolac and 2C4 main-
only does R-etodolac increase the antitumorigenic potential of tained their PPAR protein expression (Figure 6B, lanes 5 and
PPAR, as demonstrated in the transient transfection studies, 6). Xenografts treated with 2C4 alone also expressed PPAR
but it may also regulate the levels of PPARprotein via upregula- (Figure 6B, lanes 3 and 4). R-etodolac treatment did not alter
tion of phospho-ERK1/2. The latter effect may have a conse- the mRNA expression of the HER-kinase receptors (data not
quence on the antitumorigenicity of R-etodolac. shown). Based on our observed results, we propose a model
for the suggested modes of action of R-etodolac as illustrated
Combined treatment with R-etodolac and rhuMab 2C4 in Figure 7.
causes an increased suppression of prostate tumor
growth via inhibition of phospho-ERK1/2 Discussion
Since treatment with R-etodolac resulted in an upregulation of
phospho-MAP kinase and subsequent degradation of PPAR The transcription factor PPAR has been described as an impor-
tant antitumorigenic molecule involved in the control of cellprotein, we reasoned that inhibiting phospho-MAP kinase
should increase the efficacy of R-etodolac. To prevent MAP growth and differentiation (Tontonoz et al., 1994a). Accordingly,
PPAR ligands, troglitazone, rosiglitazone, and 15-deoxy-kinase activation and subsequent PPAR degradation, we
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Figure 7. Proposed model of R-etodolac action
R-etodolac transactivates PPAR activity, thereby modulating expression of
genes contributing to tumor growth inhibition. This transactivation decreases
cyclin D1 expression, which aids in tumor growth. R-etodolac treatment,
Figure 6. Inhibition of MAP kinase by 2C4 prevents R-etodolac-induced deg- while decreasing cyclin D1 expression via the PPAR pathway, also induces
radation of PPAR protein, thus promoting efficacy of R-etodolac cyclin D1 via phospho-MAPK (Lavoie et al., 1996). Cyclin D1 is known to
A: The response of CWRSA6 tumors to R-etodolac (closed diamond) admin- repress PPAR expression and transactivation (Wang et al., 2003). Phospho-
istered at 200 mg/kg via daily o.g., or 2C4 (closed square) administered MAPK induction by R-etodolac may or may not be a PPAR-dependent
at 20 mg/kg via interperitoneal injection, or a combination regimen of effect. Phospho-MAPK phosphorylates PPAR, leading to an inactivation of
R-etodolac and 2C4 (open square) at the previously stated doses. Therapy PPAR transcriptional activity due to decreased ligand affinity and unbiqui-
initiated on day 6. Results are presented as mean tumor volume (n  tin-mediated proteosome degradation of the PPAR receptor (Camp and
10)  SE. Tafuri, 1997). It is unknown how R-etodolac stimulates phospho-MAPK activ-
B: Western blot analysis showing PPAR1 expression in lysates prepared from ity; however, the additive antitumor effect of 2C4 and R-etodolac impli-
the R-etodolac and 2C4 combination efficacy studies involving the andro- cates the involvement of the HER-kinase axis as a possible activator of
gen-independent CWRSA6 human prostate xenograft tumors following 22 phospho-MAPK. The numbers 1, 2, 3, and 4 refer to the HER-kinase receptors
days of treatment. Lanes 1 and 2 represent R-etodolac-treated tumors, HER-1, HER-2, HER-3, and HER-4, respectively. Red circles refer to ligands
lanes 3 and 4 represent tumors receiving 2C4 alone, and lanes 5 and 6 that can stimulate the HER-kinase receptors.
represent tumors receiving a combination of R-etodolac and 2C4.
ized in terms of PSA progression, androgen receptor status,

-12,14-prostaglandin J2 have demonstrated growth inhibition and dependence on HER-kinase axis. These models representof prostate cancer cell lines that express an appreciable level of
two distinct stages of prostate cancer, i.e., the androgen-depen-PPAR (Mueller et al., 2000; Segawa et al., 2002). Furthermore,
dent (LuCaP-35) stage and the androgen-independent (CWRSA6)treatment of prostate cancer patients with troglitazone has been
stage (Corey et al., 2003; Nagabhushan et al., 1996). The activityshown to lower serum PSA levels (Mueller et al., 2000).
of R-etodolac did not appear to distinguish between the andro-Here we describe a PPAR transactivator, R-etodolac.
gen-dependent and -independent models in terms of its effi-R-etodolac is a stable stereoisomer of an approved nonsteroidal
cacy. Androgens play a critical role in prostate cancer survivalanti-inflammatory drug lacking cyclo-oxygenase inhibitory ac-
and progression, which is why androgen ablation therapy is thetivity that can effectively suppress the growth of prostate cancer
accepted first line of treatment for metastatic disease. Prostatexenograft models without apparent morbidity. Our study dem-
cancer subsequently progresses to an androgen-independentonstrates that R-etodolac displays a potent transactivation ac-
state, the underlying mechanisms for which are not clear. Wetivity in the presence of PPAR in cell culture-based transient
focused our subsequent studies on the androgen-independenttransfection assays. This activity is dose dependent and is com-
model since there is an urgent need in the field to identify newparable to the established NSAID PPAR agonist, indomethacin.
therapies to treat this cancer state.We support the notion that R-etodolac is a PPAR transactivator
We propose that the primary mechanism of antitumor activ-by using CD36 expression and the uptake of neutral lipids as a
ity exerted by R-etodolac is through the enhancement of tran-marker of adipocyte differentiation in the presence of R-etodolac
scriptional activity of the PPAR receptor. PPAR is well docu-and PPAR. In accordance with these observations, o.g. admin-
mented to have an effect on cell cycle progression through theistration of R-etodolac led to a significant reduction in estab-
repression of the cyclin D1 promoter (Wang et al., 2001). Cyclinlished tumor volumes of PPAR-expressing androgen-depen-
D1 determines the rate of progression of mammary epithelialdent and androgen-independent tumors.
cells through the G1 phase in response to mitogenic and onco-We chose two xenograft models for our studies, CWRSA6
and LuCaP-35, since these models have been well character- genic signals (Lee et al., 2000). Accordingly, we observed a
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downregulation in cyclin D1 gene expression following R-etodo- petuate the inhibition of cyclin D1 through the maintenance of
the PPAR protein and through the abrogation of phospho-lac treatment of prostate cancer cell lines. R-etodolac may also
contribute to tumor inhibition via upregulation of apoptosis via MAP kinase activity, thus overcoming the autoresistance to
R-etodolac. The combination study also supports the notionthe Wnt/-catenin pathway (Lu et al., 2004).
Following 2–3 weeks of treatment with R-etodolac, xeno- that the absence of PPAR expression in R-etodolac-treated
xenografts is not the result of selection against PPAR-positivegrafts exhibit PPAR protein loss. This loss of PPAR protein
is a posttranscriptional event because no change in PPAR cells. Taken together, these observations suggest that R-etodo-
lac-mediated growth inhibition is achieved through activationmRNA expression was observed. This lack of PPAR protein
may be explained either through posttranscriptional degradation of the PPAR receptor while controlling this activity through a
mechanism of autoresistance.of PPAR or through selection against PPAR-positive cells.
Selection against PPAR-positive cells is ruled out by the results Based on the results of the combination therapy with the
HER-kinase-specific antibody, 2C4, our study suggests thatof the combination drug therapy study discussed later. It may
be tempting to conclude that the antitumorigenic effect of R-etodolac activates phospho-MAP kinase through stimulation
of the HER-kinase axis. It is not known if this is a PPAR-R-etodolac works through loss of PPAR protein, but this is not
the case. PPAR protein loss as a mechanism of R-etodolac dependent event. Nevertheless, this observation reveals an im-
portant crosstalk between the HER-kinase axis and PPARfunction is refuted by immunoblots of the time course experi-
ment that reveal an upregulation of the PPAR receptor in the pathway in prostate tumorigenesis. The HER-kinase axis is a
positive regulator of prostate cancer cell survival, as demon-majority of the animals 24 to 72 hr post-R-etodolac treatment
(data not shown). The time period of PPAR upregulation in strated by growth inhibition curves of prostate xenografts (80%)
by the HER2-specific mAb, 2C4 (Agus et al., 2002). In our study,xenografts receiving R-etodolac coincides with the peak in
PPAR transcriptional activity in cell culture-based assays fol- 2C4 growth inhibition is additive to that achieved with R-etodo-
lac alone, and it also rescues PPAR protein from degradation.lowing R-etodolac administration. These results strengthen the
idea that the initial effect of R-etodolac is the increase in PPAR These studies suggest the involvement of the HER-kinase axis
in PPAR degradation and also support the proposed modelactivity. Our hypothesis is that the observed loss of PPAR
protein is subsequent to PPAR activation since an essential of autoresistance of R-etodolac. Other studies have shown that
HER2 mRNA overexpression enhances the expression ofrequirement for PPAR degradation is the ligand-induced con-
formational change of the receptor, which is associated with PPAR (Yang et al., 2003); however, we did not observe any
change in HER2 receptor levels. While R-etodolac treatmenttranscriptional activation (Hauser et al., 2000).
R-etodolac has the unique ability to regulate the levels of did not alter the mRNA levels of HER-kinase receptors (data
not shown), it is possible that the PPAR transactivator rendersPPAR receptors expressed in a cell. This is an important con-
cept since increased transcriptional activity of PPAR under the receptors constitutively active or increases the concentra-
tion of endogenous ligands. Activation of MAP kinase by ligandscertain circumstances has been reported to enhance colon can-
cer progression (Saez et al., 1998). A well-documented mecha- such as epidermal growth factor and platelet-derived growth
factor induce the phosphorylation of PPAR1 on Ser82 andnism utilized to negatively regulate PPAR transcriptional activ-
ity is via phosphorylation of PPAR by MAP kinase (Camp and decrease its ability to activate transcription (Camp and Tafuri,
1997). In light of these results, we propose a potential modelTafuri, 1997; Floyd and Stephens, 2002; Hauser et al., 2000).
This phosphorylation event reduces ligand binding affinity of (Figure 7) for the regulation of PPAR by R-etodolac in prostate
cancer xenografts. More experiments will be needed to furtherPPAR and leads to a downregulation of the PPAR protein
levels by ubiquitin proteosome-mediated degradation (Floyd elucidate the mechanism by which R-etodolac activates the
HER-kinase axis.and Stephens, 2002; Shao et al., 1998). Phosphorylation has
also been documented for regulation of the progesterone recep- An intriguing observation in our study has been that neutral
lipid uptake, but not transactivation of PPAR or tumor growthtor (Lange et al., 2000; Shen et al., 2001). Our observation that
treatment with R-etodolac leads to an upregulation of phospho- inhibition, was seen at lower doses (1 M) of R-etodolac. It is
known that modulation of lipid-related genes by PPAR trans-MAP kinase and a subsequent loss of PPAR protein suggests
a similar mechanism of regulation. We hypothesize that the loss activators occur at several log concentrations lower, closer to
the Kd of PPAR, than the concentrations required to produceof PPAR protein, a target of R-etodolac, may be a mechanism
of “autoresistance” to the drug. The loss of PPARprotein would anticancer activity or inhibit cytokines via PPAR (Koeffler,
2003). The concern still remains regarding the high R-etodolacalso compromise the ability of R-etodolac to repress cyclin D1.
Additionally, induction of phospho-MAP kinase by R-etodolac dosage required to see a visible effect on tumor growth inhibi-
tion. The high dosage required can be explained due to thewould lead to an increase in cyclin D1 since MAP kinase induces
the cyclin D1 promoter through a phospho-PPAR-independent autoresistance phenomenon observed with R-etodolac. Autore-
sistance limits the ability of R-etodolac to cause an effectivemechanism (Wang et al., 2001; Watanabe et al., 1998). In-
creased cyclin D1 is documented to repress PPAR expression decrease in cyclin D1 expression via PPAR. Therefore, a dose
increase of the drug may be required to overcome autoresis-and transactivation, limiting its antitumorigenic potential (Wang
et al., 2003). These events would add to the mechanism of tance to R-etodolac by shifting activity of the system toward
the PPAR-dependent pathway and to observe a net effectautoresistance of R-etodolac.
The autoresistance phenomenon can be overcome by use of on tumor inhibition, since the ubiquitination and proteosome-
mediated degradation of PPAR will become a limiting step ata combination regimen of R-etodolac and 2C4. The combination
regimen promotes maintenance of PPAR protein in the xeno- some concentration of R-etodolac, thus increasing the availabil-
ity of the drug target in the tumors (PPAR) and an increasedgraft, which correlates with increased antitumorigenicity. Treat-
ment with 2C4 in combination with R-etodolac would also per- antitumorigenic effect. However, an important point to remember
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CTGTGTCAACCA-3, (P) 5-TGATACACTGTCTGCAAACATATCACAAGAAis that R-etodolac does not have COX-inhibitory activity and can
ATGACC-3; -actin: (F) 5-GCGCGGCTACAGCTTCA-3, (R) 5-TCTCCTTAaccumulate to high levels in the plasma without causing any in-
ATGTCACGCACGAT-3, (P) 5-CACCACGGCCGAGCGGGA-3. The mRNAflammation-induced damage to internal organs in nude mice.
expression of cyclin D1 (Takayasu et al., 2001) and the HER-kinase receptors
In summary, this study demonstrates tumor growth inhibi- (Agus et al., 2002) were analyzed using primer sets as previously described.
tion by R-etodolac via a PPAR-dependent pathway and high- The one-step RT-PCR cycling conditions for all primer sets were as
lights a crosstalk mechanism between PPAR and HER-kinase follows: 30 min at 48C for RT step; 10 min at 95C for AmpliTaq Gold
activation; and 40 cycles for cDNA dentauring (95C, 15 s) and annealing/signaling pathways in prostate tumorigenesis.
elongation (60C for 1 min) steps. PCR reactions for each template were
done in triplicate using 1 g of total RNA per sample. Each gene-specificExperimental procedures
primer pair was tested on standard 384-well plates. Standard curves were
constructed using 10–1000 ng of total RNA prepared from the CWRSA6Tumor models
tumor line. All experiments were optimized such that the threshold cycleThe xenograft studies were performed as previously described (Agus et al.,
(CT) from triplicate reactions did not differ by more than one cycle number.1999a, 1999b). 4- to 6-week-old nude mice were obtained from National
The comparative CT method (PE Applied Biosystems, Foster City, CA)Cancer Institute-Charles Rivers Laboratories and maintained in pressurized
was used to determine relative quantification of gene expression for eachventilated caging at the Cedars-Sinai Medical Center vivarium. Male animals
gene compared with the -actin control. First, the CT values from the -actinwere subcutaneously inoculated with minced tumor tissue from the andro-
reactions were averaged for each triplicate. Next, the CT values from thegen-dependent LuCaP-35 xenografts (Corey et al., 2003), and females re-
gene-of-interest reactions were averaged. The gene-of-interest average wasceived the androgen-independent CWRSA6 xenografts that were obtained
divided by the -actin average to take into account the variability of totalby selecting tumors for regrowth and increased serum PSA after androgen
RNA.withdrawal (Agus et al., 1999a). All lines were injected together with reconsti-
tuted basement membrane (Matrigel; Collaborative Research, Bedford, MA)
Western blot analysisand RPMI 1640 supplemented with 100 g/ml penicillin and 100 g/ml
Immunoblots were performed as previously described (Towbin et al., 1979)streptomycin as described previously (Nagabhushan et al., 1996; Wainstein
using aliquots of tumor lysates (100 g per lane) or lysates from LNCaPet al., 1994). To maintain serum testosterone levels (for the LuCap-35 line),
cells (100g per lane). Protein concentration was determined with a Bradfordmice were subcutaneously implanted with 12.5 mg sustained release testos-
Assay (Bio-Rad, Hercules, CA). The lysates were separated on 10% SDSterone pellets (Innovative Research of America, Sarasota, FL) 1 week before
polyacrylamide gels and transferred onto nitrocellulose filters. The mem-receiving the tumor cell inoculation. For single agent efficacy studies, treat-
branes were incubated overnight at 4C with antibodies against PPARments consisted of daily oral gavage (o.g.) of 200 mg/kg R-etodolac
(Sc-7273; Santa Cruz Inc., Santa Cruz, CA), ERK1 (Sc-94; Santa Cruz),(Salmedix, Inc.) in water, supplemented with 0.5% Methycellulose and 0.5%
phospho-p44/42 MAP kinase (9101S; Cell Signal, Beverly, MA), and cyclinPolysorbate 80. The combination regimen study consisted of daily o.g. of
D1 (554180; BD Pharmingen, San Diego, CA), in parallel with anti--actin200 mg/kg R-etodolac and twice weekly intraperitoneal (i.p.) injection of 20
antibodies (A2066; Sigma, St. Louis, MO) and washed well before incubatingmg/kg 2C4 (Genentech, South San Francisco, CA) in phosphate-buffered
with the appropriate -mouse or -rabbit secondary antibody conjugatedsaline. Tumors were measured every 3–4 days with vernier calipers, and
with horseradish peroxidase (Amersham Biosciences, UK).tumor volumes were calculated by the formula /6  (larger diameter) 
(smaller diameter)2. Animals with palpably established tumors of at least 65
Cell culture and transfectionmm3 were designated to treatment groups.
Raw 267.4 cells were maintained in Dulbecco’s modified eagle mediumA time course study was implemented using R-etodolac-treated
(DMEM) with high glucose (GIBCO, Grand Island, NY) supplemented withCWRSA6 xenografts. 14-day-old CWRSA6 xenografts, with palpably estab-
10% fetal bovine serum (FBS), 100 g/ml penicillin, and 100 g/ml strepto-lished tumors of at least 1000 mm3, were randomized into two cohorts,
mycin at 37C and 5% CO2. For transfection, cells were seeded in 12-experimental and control. The experimental groups received daily o.g. of
well plates for at least 24 hr prior to transfection. At approximately 50%200 mg/kg R-etodolac and were sacrificed 24 hr (n  3), 48 hr (n  3), and
confluence, cells were transiently transfected using the FuGene transfection72 hr (n  3) postinitiation of treatment. The control cohort was sacrificed
reagent (Roche Diagnostics GmbH, Mannheim, Germany) according to theat the start of the study.
manufacturer’s instructions, with 0.5 g reporter plasmid (AOx)3-TK-Luc,
0.1 to 0.2 g of control plasmid pCMXgal, 0.1 g PPAR expressionStatistical analysis of the xenograft experiments
plasmid, and carrier DNA for a total of 1 g DNA per well. After 16 hr, thePairwise differences between the tumor volumes of the treatment groups
cells were washed, and fresh medium containing the appropriate amountwere compared over time using a permutation test. The null hypothesis for
of drugs, prepared in 0.5% DMSO, was added to the cells for another 24this test is that treatment has no differential effect on the tumor volumes
hr. The cells were treated with either vehicle alone (DMSO), indomethacin,over time. The statistic (SS_Dev) used to test the hypothesis was the sum
rosiglitazone, or varying concentrations of R- or S-etodolac.of the squared differences between the mean tumor volumes summed over
For luciferase assays, the cells were lysed in potassium phosphateall time points. The statistic reflects the amount by which the trajectories of
buffer containing 1% Triton X-100, and light emission was detected in theaverage tumor volume of the two treatment groups are different (Agus et
presence of luciferin using a microtiter plate luminometer (MicroBeta TriLux,al., 1999b).
Gaithersburg, MD). Luciferase values were normalized for variations in trans-
fection efficiency using -galactosidase as internal control. The results areRNA extraction and real-time quantitative RT-PCR
Total RNA was extracted from prostate tumors or the LNCaP cell line using expressed as relative luciferase units (RLU). The luciferase activity values
represent the mean of a minimum of three independent transfections per-the Trizol reagent (Invitrogen, San Diego, CA). Samples were heated at 95C
for 3 min and snap-cooled before proceeding with DNase I treatment to formed in triplicate.
22Rv1 and LNCaP prostate carcinoma cell lines and human monocyticprevent RNA/DNA hybridization. DNase I (Ambion, Austin, TX) was used to
remove any genomic DNA that might interfere with the reaction. Samples THP-1 cells were obtained from the American Type Culture Collection (Rock-
ville, MD) and maintained in RPMI 1640 medium supplemented with 10%were treated with DNase I for 1 hr at 37C. The RNA yield was quantified
spectrophotometrically. Total RNA was reverse-transcribed into cDNA, and FBS, 100 g/ml penicillin, and 100 g/ml streptomycin (GIBCO). To assess
MAP kinase phosphorylation, 22Rv1 cells were seeded into 100 mm dishesPCR was performed in the same reaction using TAQman One-Step RT-
PCR Master Mix Reagents Kit (Applied Biosystems, Foster City, CA). The and allowed to attach for a period of 18 hr. The media was then replaced
with phenol red-free and serum-free RPMI1640, with 100 g/ml penicillinsequences of the primer/probe sets used for this analysis are as follows. F
and R are the forward and reverse primers, respectively, and P is the fluores- and 100 g/ml streptomycin  R-etodolac for the indicated times. MAP
kinase activation was assessed by Western blot analysis using methodscent-labeled probe. PPAR: (F) 5-CGGGCCCTGGCAAAAC-3, (R) 5-CGCC
CTCGCCTTTGCT-3, (P) 5-TTTGTATGACTCATACATAAAGTCCTTCCCG described above. LNCaP cells were treated with R-etodolac at 200, 400,
and 600 M concentrations for 18 hr. Total protein or RNA was isolatedCTG; PPAR2: (F) 5-CCCAGAAAGCGATTCCTTCA-3, (R) 5-AATGGCATCT
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gamma. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem.using methods as described previously. Cyclin D1 protein and mRNA expres-
278, 5845–5853.sion were assessed by Western blot and quantitative RT-PCR-based assay
as previously described. Corey, E., Quinn, J.E., Buhler, K.R., Nelson, P.S., Macoska, J.A., True, L.D.,
and Vessella, R.L. (2003). LuCaP 35: a new model of prostate cancer progres-
Flow cytometric analysis of CD36 sion to androgen independence. Prostate 55, 239–246.
Human monocytic THP-1 cells were treated for 5 days with 200 M etodolac
Camp, H.S., and Tafuri, S.R. (1997). Regulation of peroxisome proliferator-(racemic mixture) and 20 M troglitazone in the presence or absence of 40
activated receptor gamma activity by mitogen-activated protein kinase. J.ng/ml phorbol ester (TPA) for 48 hr. Cells were fixed, stained with unconju-
Biol. Chem. 272, 10811–10816.gated anti-CD36 and FITC-conjugated anti-IgG, and analyzed by flow cytom-
etry. A population of 10,000 viable cells was analyzed for each treatment. Corey, E., Quinn, J.E., Buhler, K.R., Nelson, P.S., Macoska, J.A., True, L.D.,
Data are presented as the difference in mean fluorescence between anti- and Vessella, R.L. (2003). LuCaP 35: a new model of prostate cancer progres-
CD36 antibody and control isotype-matched antibody. sion to androgen independence. Prostate 55, 239–246.
Demerson, C.A., Humber, L.G., Abraham, N.A., Schilling, G., Martel, R.R.,
Oil red O staining for neutral lipid uptake and Pace-Asciak, C. (1983). Resolution of etodolac and antiinflammatory
NIH3T3 cells stably expressing recombinant PPAR (obtained from Dr. Ron- and prostaglandin synthetase inhibiting properties of the enantiomers. J.
ald Evans, Salk Institute) were maintained in DMEM supplemented with 10% Med. Chem. 26, 1778–1780.
bovine calf serum (BCS), 100 g/ml penicillin, and 100 g/ml streptomycin
Elstner, E., Muller, C., Koshizuka, K., Williamson, E.A., Park, D., Asou, H.,(GIBCO). The cells were treated for 7 days with the indicated compounds
Shintaku, P., Said, J.W., Heber, D., and Koeffler, H.P. (1998). Ligands forand concentrations and stained for neutral lipids with oil red O as described
peroxisome proliferator-activated receptorgamma and retinoic acid receptor(Green and Kehinde, 1974).
inhibit growth and induce apoptosis of human breast cancer cells in vitro
and in BNX mice. Proc. Natl. Acad. Sci. USA 95, 8806–8811.
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